Physician profile
Daniel D Park
NPI 1831239391
$3,378.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $321 · 2021: $682 · 2022: $1,216 · 2023: $463 · 2024: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.91 | 2020-2023 | |
| Amarin Pharma, INC. | $657.08 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $476.13 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $260.50 | 2020-2024 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $257.43 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Nestle Healthcare Nutrition INC. | $207.81 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $126.70 | 2019-2023 | Verquvo, Steglatro |
| Allergan, INC. | $124.99 | 2019 | |
| Amgen INC. | $89.70 | 2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.33 | 2021-2024 | Jardiance |
| Orthofix Medical, INC. | $35.33 | 2019-2023 | Spinal-Stim, Physio-Stim |
| Pfizer INC. | $25.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.46 | 2023 | |
| Abbott Laboratories | $21.64 | 2022 | |
| Radius Health, INC. | $19.29 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $15.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.